GlassScriptPhysician profile
Quentin Blackshear Allen
NPI 1164483301
$202,728.50
in general payments reported to CMS, 2019-2025
37 companies · $46K in 2025
The $46K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $48K · 2021: $23K · 2022: $5,760 · 2023: $9,377 · 2024: $24K · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $69K · Food and Beverage: $9,032 · Travel and Lodging: $632 · Honoraria: $86.91 · Gift: $85.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $69,395.00 |
| Food and Beverage | $9,031.57 |
| Travel and Lodging | $632.25 |
| Honoraria | $86.91 |
| Gift | $85.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $104,637.62 | 2019-2025 | Acrysof Iq Panoptix Uv Iol, Clareon, Acrysof Iq Vivity |
| Alcon Research LLC | $27,720.85 | 2019-2025 | Acrysof Iq Vivity, Clareon, Acrysof Iq Panoptix Uv Iol |
| Kala Pharmaceuticals, INC. | $19,112.24 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $12,020.24 | 2022-2025 | Envista Envy Iol, Crystalens Accommodating Iol (At-52ao), Envista Mx60 Iol |
| Sun Pharmaceutical Industries INC. | $11,209.97 | 2019-2025 | Cequa |
| Rxsight INC | $7,254.48 | 2022-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Eyevance Pharmaceuticals LLC | $3,935.77 | 2019-2023 | Flarex, Tobradex St |
| Johnson & Johnson Surgical Vision, INC. | $2,782.07 | 2019-2025 | Tecnis Iol, Tecnis Simplicity, Catalys System |
| Lensar, INC. | $2,179.19 | 2021-2023 | Lensar Laser System |
| Ocular Therapeutix, INC. | $2,046.36 | 2020 | |
| Glaukos Corporation | $1,893.90 | 2019-2024 | Idose, Istent Trabecular Micro-Bypass System Model Is3 |
| Allergan, INC. | $1,742.60 | 2019-2022 | |
| Sight Sciences, INC. | $1,598.05 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Abbvie INC. | $970.61 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Rayner Intraocular Lenses Limited | $706.12 | 2022-2025 | Rayone Aspheric, Rayone Emv, Rayone Spheric |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$120,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Quentin Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.